User profiles for FAIROOZ F. KABBINAVAR

Fairooz Kabbinavar

Verified email at mednet.ucla.edu
Cited by 44126

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

FF Kabbinavar, J Schulz, M McCleod, T Patel… - Journal of Clinical …, 2005 - ascopubs.org
Purpose Bevacizumab, a monoclonal antibody against vascular endothelial growth factor,
increases survival when combined with irinotecan-based chemotherapy in first-line treatment …

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

FF Kabbinavar, J Hambleton, RD Mass… - Journal of clinical …, 2005 - ascopubs.org
Purpose Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA), a recombinant,
humanized anti–vascular endothelial growth factor monoclonal antibody that inhibits tumor …

Overexpression of AKT2/protein kinase Bβ leads to up-regulation of β1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells

MJ Arboleda, JF Lyons, FF Kabbinavar, MR Bray… - Cancer research, 2003 - AACR
To determine how AKT2 might contribute to tumor cell progression, a full-length, wild-type,
human AKT2/protein kinase B (PKB)β cDNA was transfected into a panel of eight human …

Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study

…, MU Yood, J Berlin, PJ Flynn, FF Kabbinavar… - The …, 2009 - academic.oup.com
Background. The Bevacizumab Regimens’ Investigation of Treatment Effects (BRiTE) study
is a prospective, observational cohort study designed to elucidate safety and effectiveness …

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

RM Bukowski, FF Kabbinavar, RA Figlin… - Journal of clinical …, 2007 - ascopubs.org
Purpose Bevacizumab (Bev) has clinical activity in advanced renal cell carcinoma (RCC),
and, when combined with erlotinib (Erl), has shown encouraging objective response rate (ORR…

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium

CJ Sweeney, BJ Roth, FF Kabbinavar… - Journal of Clinical …, 2006 - ascopubs.org
Purpose To assess the antitumor activity and toxicity of pemetrexed as second-line chemotherapy
in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the …

Hypoxia-inducible factor 1α in clear cell renal cell carcinoma

…, MK Berkman, MD Kleid, H Yu, FF Kabbinavar… - Clinical cancer …, 2007 - AACR
Purpose: Hypoxia-inducible factor-1α (HIF-1α) plays an important role in tumoral adaptation
to hypoxic conditions by serving as a transcription factor for several crucial proteins, …

Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma

…, N Zomorodian, J Said, FF Kabbinavar… - Journal of clinical …, 2009 - ascopubs.org
Purpose The majority of cytogenetic studies in renal cell carcinoma (RCC) have been
impaired by small sample size, retrospective character, and lack of a survival end point. We …

[PDF][PDF] Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two …

FF Kabbinavar, HI Hurwitz, J Yi, S Sarkar… - Journal of Clinical …, 2009 - researchgate.net
Purpose Colorectal cancer (CRC) occurs predominantly in older persons. To provide more
statistical power to assess risk/benefit in older patients, we examined the clinical benefit of …

Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy

…, SB Riggs, N Zomorodian, FF Kabbinavar… - … Biomarkers & Prevention, 2009 - AACR
Purpose: To identify the molecular signature of localized (N0M0) clear cell renal cell carcinoma
(RCC) and assess its ability to predict outcome. Methods: Clinical characteristics and …